Importantly, while Cilengitide was conceptualized to target RGD-binding integrins on endothelial cells to inhibit tumor angiogenesis, perhaps through abrogation of the FAK/Src/AKT pathway10,107, this approach is complicated by the presence of these integrins on additional cell types within the TME. This evidence concerns the gene SRC and neoplasm.